WVE (Wave Pharma) Rega marang bathi mangsa ngarep
Wave Life Sciences is preparing to launch innovative RNA-based drugs to combat genetic pathologies. The business relies on a unique stereopurity platform, capturing the precision medicine niche. Simultaneously, the company is implementing eco-friendly molecule synthesis to comply with ESG standards. The company's forward P/E ratio demonstrates earnings growth potential, where the 0.00 mark serves as the current real-time valuation.
Ringkesan rincian data analitis Wave Pharma (WVE)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Wave Life Sciences|WVE - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Wave Life Sciences|WVE - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Wave Life Sciences Ltd|WVE - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Wave Life Sciences|Rasio cepet wavelifesciences.com
- statistik bathi lan rasio pasar:
WVE - Asil keuangan resik|Proyeksi bathi mangsa ngarep Wave Life Sciences|WVE - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Wave Life Sciences Corp|WVE - Rasio P/E diaturake wutah|Pangali EV/EBITDA Wave Life Sciences Ltd|WVE - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Wave Life Sciences|WVE - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan wavelifesciences.com|WVE - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Wave Life Sciences
- data pendapatan lan penerimaan dodolan:
Pambiji fundamental:WVE Wave Life Sciences Ltd.
Investors must determine an asset's fair value through the lens of future earnings. This ratio compares the current quote with projected net income, revealing market imbalances between price and actual potential. By analyzing changes in the company's forward P/E level, one can identify phases of irrational exuberance or undervaluation. For Wave Life Sciences (WVE), this balance is maintained by retaining rare RNA therapy specialists. A stable workforce minimizes the risks associated with the realization of forecasts.
Pesaing utama
Prakiraan rega marang bathi TEM (Tempus Labs)|QGEN (Qiagen NV) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Ionis Pharma IONS|Repligen Inc. - Rega marang bathi mangsa ngarep|Avidity Biosciences - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi crisprtx.com CRSP|WGS: Pangali Forward P/E|Rasio rega marang bathi sing dikarepake RARE (Ultragenyx Pharmaceutical Inc.)|BEAM (Beam Therapeutics Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Sarepta Corp SRPT|Prakiraan rega marang bathi TWST (Twist Bioscience)|TXG (10xgenomics.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Intellia Therapeutics, Inc. NTLA|Kapitalisasi marang proyeksi bathi Stoke Therapeutics Inc (STOK)|BioLife Corp - Pangali Forward P/E|Maze Therapeutics Corp (MAZE) - Prakiraan rega marang bathi|SION: Pangali Forward P/E|PRME - Kapitalisasi marang proyeksi bathi|TSHA (Taysha Gene Therapies, Inc.) - Pangali Forward P/E|Rasio prakiraan rega marang bathi uniQure NV QURE|Rega marang bathi mangsa ngarep MeiraGTx PLC (MGTX)|REGENXBIO Corp - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E SLDB (Solid Biosciences Inc.)|OCGN - Prakiraan rega marang bathi|PacBio - Pangali Forward P/E|Rasio prakiraan rega marang bathi Benitec Biopharma Inc|Design Pharma (DSGN) - Rega marang bathi mangsa ngarep|RCKT - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi FDMT|Prakiraan rega marang bathi Lexeo (LXEO)|Prakiraan rega marang bathi KRRO (Korro Bio, Inc.)|Rega marang bathi mangsa ngarep EDIT (Editas Medicine Inc)|Pangali Forward P/E SLN (Silence Therapeutics Inc.)|ProQR (PRQR) - Rasio prakiraan rega marang bathi|Codexis Bio - Pangali Forward P/E|SGMO (sangamo.com) - Rasio rega marang bathi mangsa ngarep|nautilus.bio (NAUT) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep MGX|DTIL (Precision BioSciences, Inc.) - Pangali Forward P/E|Pangali Forward P/E Generation Bio Corp|Prakiraan rega marang bathi BOLD (Boundless Bio, Inc.)|Prakiraan rega marang bathi exicuretx.com XCUR|Pangali Forward P/E IMNN (Imunon)|Pangali Forward P/E Phio Pharmaceuticals Corp PHIO|MBIO: Prakiraan rega marang bathi|RNAZ: Rega marang bathi mangsa ngarep|BNGO: Pangali Forward P/E|Rasio prakiraan rega marang bathi adnas.com (APDN)|Prakiraan rega marang bathi BLUE|IPA: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Omega (OMGA)|Rega marang bathi mangsa ngarep OMIC (Singular Genomics Corp)|Pangali Forward P/E RGLS (Regulus Therapeutics)|Kapitalisasi marang proyeksi bathi syros.com (SYRS)|Telesis Bio - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake TCON|UBX: Pangali Forward P/E
